Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Sanofi, Hanmi seal diabetes licence deal for up to $4.2 bln (updated)

* Hanmi to receive upfront payment of 400 mln euros 
    * Hanmi eligible for up to 3.5 bln euros in sales 
    * Sanofi to obtain exclusive worldwide licence 
 
 (Adds details) 
    PARIS, Nov 5 (Reuters) - Sanofi  SASY.PA  signed a licence 
deal with Hanmi Pharmaceutical  128940.KS  to develop 
experimental, long-acting diabetes treatments, the French 
drugmaker said on Thursday, in a deal to revive its diabetes 
division. 
    Korea-based Hanmi will receive an upfront payment of 400 
million euros ($434 million) and is eligible for up to 3.5 
billion euros in development, registration and sales milestones 
as well as double-digit royalties on net sales, Sanofi said. 
    In exchange, Sanofi will obtain an exclusive worldwide 
licence to develop and commercialise a series of therapies. 
Hanmi will retain an exclusive option to co-commercialise the 
products in Korea and China.  urn:newsml:reuters.com:*:nHUG7mbBM5 
    Shares in Sanofi were up 1.1 percent at 92.78 euros at 0905 
GMT, outperforming the CAC 40 Index  .FCHI . 
    Nearly 400 million people worldwide have diabetes, with type 
2 accounting for more than 90 percent of cases. Without proper 
treatment or lifestyle changes those numbers are expected to 
grow substantially. 
    The transaction highlights Sanofi's willingness to boost its 
diabetes division, a major profit earner that has been hurt by 
growing competition, especially in the United States. 
    The company, which will unveil a five-year strategic plan on 
Friday, surprised investors last week when it said revenues at 
the division would keep falling until 2018.  urn:newsml:reuters.com:*:nL8N12T0VP 
    Although he did not refer specifically to the diabetes 
business, Sanofi Chief Executive Olivier Brandicourt told 
reporters then that company would consider possible 
acquisitions, as well as licensing deals, in the coming months. 
    The agreement announced on Thursday also shows the growing 
power of South Korea as a force in drug research. 
    According to a study of Research and Markets published in 
May, the country is seen as one of the leaders in research and 
development in the Asia Pacific region thanks to the strong 
involvement of public and private sectors.  
($1 = 0.9225 euros) 
 
 (Reporting by Matthias Blamont; additional reporting by James 
Regan; editing by David Clarke) 
 ((james.regan@thomsonreuters.com; +33)(0)(1 49 49 53 84; 
Reuters Messaging:  james.regan.thomsonreuters.com@reuters.net)) 
 
Keywords: SANOFI HANMI/DIABETES

Recent news on Hanmi Pharm

See all news